During the past decade, novel revolutionary frontiers have been opened at the immuno-inflammatory research fields. Indeed, with the help of modern, state-of-the-art technologies (immunomics and other omics, systems biology) it was identified that the immune system is much more complex than previously thought and that its proper functions are defined by multi-directional intercellular communications between cellular (and humoral) components of innate and adaptive immunity.
Metabolic and cardiovascular (CV) diseases are among the major cause of death in Hungary and worldwide, thus impose an enormous social and economic burden. In the clinical practice there is a great need for i) the elucidation of the molecular pathomechanism of such high-burden diseases (including obesity, diabetes, heart failure), as well as for ii) the development of novel therapies, cost-effective treatments and iii) more personalized or at least targeted therapeutic approaches.
In the EU-28, cancer accounts for 25.8% of the total number of deaths, acquiring the second position behind cardiovascular diseases. In 2012, among the EU member states, the highest standardized death rates for cancer were recorded in Hungary and Croatia, both with rates over 330 per 100 000 inhabitants (EuroStat data). During the past decade(s), significant developments have been made to lower the burdens related to cancer and its complications.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739593. HCEMM supported by EU Programme: H2020-EU.4.a. – Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.
Hungarian Centre of Excellence for Molecular Medicine is a strong catalyst of reformative changes in biomedical science and in institutional research management.
National VAT number: 26307383-2-06 EU VAT number: HU26307383